| EUR(million) | 1st Half 2013 | 1st Half 2012 | Change % |
| Turnover from scientific activities Other revenues |
1.75 0.50 |
1.62 0.38 |
+8% +30 % |
| Total revenues | 2.25 | 2.00 | +12% |
| Cash position (end of period) | 2.11 | 4.16 | -49 % |
Hybrigenics total revenues for H1 2013 increased by 12% to reach €2.25 million. Revenues from protein interactions services grew by 11% (turnover and grants of €1.55 million vs. €1.40 million). The new YChemH service launched earlier this year to screen for interactions between small molecules and proteins (see Hybrigenics’ press release of January 24th) started to contribute to the additional turnover. Revenue from the drug discovery collaboration with Servier on de-ubiquitinating enzymes and their inhibitors has remained stable (€0.375 million).
Hybrigenics’ cash position on June 30th, 2013 amounted to €2.1 million compared to €3.5 million on December 31st, 2012, and €4.2 million on June 30th, 2012. During H1 2013, a total of €1.1 million has been raised from drawings on the equity line agreement with the American fund Yorkville Global Advisors; €6.5 million are still available on this line.
“Hybrigenics Services delivered a remarkable business performance during this first half of 2013. The strength of this activity encouraged Hybrigenics Services to acquire Dualsystems Biotech’s assets in this field, as announced on July 1st, 2013,” said Remi Delansorne, Hybrigenics’ CEO.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSEEuronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
***
HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
Hybrigenics
Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
vairfgbef@uloevtravpf.pbz
NewCap.
Financial communication
Julien Perez / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
uloevtravpf@arjpnc.se « back to overview